Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cheonan
Clinical trial register · South Korea

Clinical Trials in Cheonan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Seung-Jung Park3 Novartis Pharmaceuticals3 Pharmicell Co., Ltd.2 Seoul National University Hospital2 Alpine Immune Sciences, Inc.1
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Cheonan

33 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
ReadyCure Inc.
Not applicable
30
Cheonan
2026-10-26
Not yet open
Chonnam National University Hospital
Not applicable
1,252
Bucheon-si, Changwon, Cheonan, Cheongju-si, Chuncheon, Daegu, Daejeon, Gwangju
2026-09-01
Not yet open
Seoul National University Hospital
Not applicable
1,724
Ansan, Anyang, Busan, Changwon, Cheonan, Daegu, Gwangju, Incheon
2026-07-29
Recruiting
PROGAIN Trial in Gastric Cancer Surgery
NCT07488611Stomach (Gastric) Cancer
Soonchunhyang University Hospital
Phase 3
110
Cheonan
2026-02-13
Active, closed
Jetema Co., Ltd.
Not applicable
100
Cheonan, Seoul
2026-01-21
Not yet open
Inha University Hospital
Phase 4
1,898
Incheon, Ansan, Bucheon-si, Busan, Cheonan, Goyang, Goyang-si, Guri-si
2026-01-01
Active, closed
Kymera Therapeutics, Inc.
Phase 2
200
Ansan-si, Cheonan, Gyeonggi-do, Incheon, Seoul
2025-11-24
Recruiting
Deepsonbio
Not applicable
138
Cheonan, Hwaseong-si, Incheon, Seongnam-si, Suwon, Seoul
2025-11-20
Recruiting
BioNTech SE
Phase 3
558
Cheonan, Cheongju-si, Goyang-si, Seongnam-si, Seoul, Suwon
2025-10-30
Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)
ADARx Pharmaceuticals, Inc.
Phase 2
45
Wŏnju, Gyeonggi-do, Seoul, Cheonan, Daegu
2025-08-28
Recruiting
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
220
Cheonan, Guri-si, Seongnam-si, Seoul
2025-07-28
Recruiting
Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
NCT06962098Diabetic Kidney Disease (DKD)
Aptabio Therapeutics, Inc.
Phase 2
186
Ansan-si, Busan, Cheonan, Daegu, Goyang-si, Guri-si, Gwangmyeong, Incheon
2025-05-26
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Anyang, Cheonan, Daegu, Daejeon, Gangwon-do, Goyang-si, Seongnam-si, Seoul
2024-08-30
Recruiting
CMG Pharmaceutical Co. Ltd
Phase 3
240
Anyang, Buchon, Busan, Cheonan, Daegu, Daejeon, Goyang-si, Guri-si
2024-04-19
Recruiting
A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants
NCT06246123Arthritis, Rheumatoid, Colitis, Ulcerative
Eisai Korea Inc.
Observational
2,040
Cheonan, Chuncheon, Wŏnju, Ansan, Bucheon-si, Goyang-si, Gwangmyeong, Seongnam-si
2024-02-27
Active, closed
DualityBio Inc.
Phase 3
541
Busan, Wŏnju, Seongnam-si, Seoul, Suwon, Incheon, Cheonan, Ulsan
2024-01-18
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Dongan-Gu, Anyang-Si, Guri-si, Uijeongbu-si, Jongno-gu, Seodaemun-gu, Seongbuk-Gu, Cheonan, Daejeon
2023-07-06
Recruiting
Seoul National University Hospital
Phase 4
11,086
Seoul, Andong, Busan, Changwon, Cheonan, Cheongju-si, Chuncheon, Daegu
2023-03-22
Active, closed
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
NCT05732402Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
DrugPovetacicept
Alpine Immune Sciences, Inc.
Phase 1/2
72
Cheonan, Anyang-si, Goyang-si, Guri-si, Seoul, Suwon
2023-03-15
Active, closed
AriBio Co., Ltd.
Phase 3
1,535
Seongnam-si, Gwangju, Seoul, Chuncheon, Incheon, Cheonan, Daegu, Guri-si
2022-12-23
Recruiting
CHA University
Not applicable
240
Cheonan, Ansan-si, Goyang-si, Seongnam-si, Yangsan, Changwon, Hwasun, Busan
2022-08-01
Recruiting
Pharmicell Co., Ltd.
Observational
100
Ansan, Bucheon-si, Cheonan, Chuncheon, Gangneung-si, Seoul, Wŏnju, Yongin
2021-09-09
Recruiting
Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy
NCT04416581Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction
Duk-Woo Park, MD
Phase 4
3,320
Anyang, Bucheon-si, Busan, Changwon, Cheonan, Cheonju, Chuncheon, Daegu
2021-05-12
Recruiting
Pharmicell Co., Ltd.
Phase 3
200
Ansan, Bucheon-si, Cheonan, Chuncheon, Gangneung-si, Seoul, Wŏnju, Yongin
2021-04-19
Active, closed
Atrasentan in Patients With Proteinuric Glomerular Diseases
NCT04573920IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
DrugAtrasentan
Novartis Pharmaceuticals
Phase 2
103
Cheonan, Anyang-si, Seoul
2021-03-15
Active, closed
Regeneron Pharmaceuticals
Observational
100
Cheonan
2021-02-05
Active, closed
pharmaand GmbH
Phase 3
1,097
Goyang-si, Seongnam-si, Incheon, Cheonan, Seoul, Suwon
2018-05-14
Active, closed
Kyung Hee University Hospital at Gangdong
Phase 3
358
Busan, Cheonan, Chuncheon, Daegu, Daejeon, Hwasun, Iksan, Seoul
2016-12-07
Recruiting
Kee-joon Choi
Phase 4
140
Bucheon-si, Busan, Cheonan, Daegu, Daejeon, Gangneung, Gwangju, Iksan
2016-11-29
Active, closed
IRIS-Synergy Cohort in the IRIS-DES Registry
NCT02720419Coronary Artery Disease
Jung-min Ahn
Observational
3,000
Bucheon-si, Busan, Cheonan, Chuncheon, Daegu, Daejeon, Gangneung, Gwangju
2016-08
Recruiting
Seung-Jung Park
Observational
4,000
Seoul, Busan, Cheonan, Daegu, Daejeon, Ilsan, Incheon, Jeju City
2016-07
Active, closed
IRIS-Onyx Cohort in the IRIS-DES Registry
NCT02593994Coronary Artery Disease, Arterial Occlusive Diseases, Cardiovascular Diseases, Percutaneous Transluminal Angioplasty
Seung-Jung Park
Observational
4,500
Seoul, Anyang, Bucheon-si, Cheonan, Chuncheon, Daegu, Daejeon, Gangneung
2015-10
Recruiting
Observational Study for Left Main Disease Treatment
NCT01341327Coronary Artery Disease
Seung-Jung Park
Observational
10,000
Anyang, Bucheon-si, Busan, Cheonan, Cheongju-si, Daegu, Daejeon, Gangneung
2007-07
Rows per page Showing 1–33 of 33
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/cheonan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 33 of those studies with a site in Cheonan.

How many clinical trials are recruiting in Cheonan?

17 of the 33 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 3 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Cheonan), 33 studies
PhaseStudiesRecruitingShare
Phase 311533.3%
Observational7421.2%
Not applicable6318.2%
Phase 24212.1%
Phase 44312.1%
Phase 1/2103%

Most active sponsors

Lead sponsors with the most studies (Cheonan)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals31
Seung-Jung Park32
Pharmicell Co., Ltd.22
Seoul National University Hospital21
ADARx Pharmaceuticals, Inc.11
Alpine Immune Sciences Inc, A Subsidiary of Vertex10
Alpine Immune Sciences, Inc.10
Aptabio Therapeutics, Inc.11
AriBio Co., Ltd.10
BioNTech SE11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.